Bora promotes all market activities with integrity, transparency, and compliance. To protect safety and public interest, the Company enforces its” Marketing Code of Conduct” and the “Pharmaceutical Marketing Behavior Guidelines.” All employees and third parties are obligated to adhere to these guidelines, as well as stricter local laws where applicable.
Sales and Promotional Practices
For distributed or licensed products, Bora follows the marketing standards of the original manufacturers.
Upsher-Smith Laboratories, our U.S. subsidiary, adopts the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals (HCPs) and complies with relevant U.S. Food and Drug Administration (FDA) regulations
In Taiwan, Bora Health (part of Sunway Biotech) adheres to the Taiwan Food and Drug Administration (TFDA) regulations and references the Marketing Code established by the International Research-Based Pharmaceutical Manufacturers Association (IRPMA) to develop comprehensive internal operating procedures.
Bora Health, a subsidiary of Sunway group, promotes products through a dedicated sales team and a network that includes medical centers, hospitals, clinics, pharmacies and distributors. The company organizes or sponsors various therapeutic academic exchange activities and conferences to support proper product use. All marketing and sales activities comply strictly with legal and ethical standards, ensuring interactions with healthcare professionals are centered on patient welfare and healthcare advancement.
Packaging and Product Labeling
Clear and accurate labeling is vital for safe medication use. Bora ensures all product labels fully comply with review guidelines, covering composition, indications, usage instructions, dosage, and precautions, with inserts or leaflets included. All packaging reflects content approved by the Taiwan Food and Drug Administration (TFDA).
From January to December 2024, Bora Group had no violations related to drug labeling or marketing communications.
Drug Advertising Compliance
Bora follows strict advertising regulations to prevent misleading content. Internal SOPs ensure promotional materials are approved by health authorities as required under the Pharmaceutical Affairs Act.
Marketing materials must be clear, accurate, balanced, and evidence-based—free from exaggeration or false claims. Educational events must focus on product information or scientific content. Sales teams receive quarterly training on product and disease knowledge and strictly follow the approved marketing plan.
Product Safety Monitoring and Reporting
All Bora products are licensed by the TFDA and comply with health and safety regulations. From January to December 2024, there were no regulatory violations.
Bora collaborates with manufacturers and suppliers to report adverse drug reactions and product defects, serving as a communication bridge to provide investigation feedback to the marketing authorization holder or Taiwan’s Food and Drug Administration through the “Drug Quality and Therapeutic Inconsistency Reporting System.”
Adverse Drug Reaction Management
Bora has implemented a “Standard Operating Procedure for Drug Safety Monitoring” with a Drug Safety Team dedicated to handling adverse drug reactions. All reported cases are documented and processed according to regulations while maintaining personal data privacy.
From January to December 2024, 0 adverse drug reaction cases were reported.
Product Recall and Complaint Handling
To uphold consumer trust, the company has developed “Complaint Handling SOPs” and “Recall Handling SOPs”. These procedures ensure prompt investigation and effective corrective actions.
In 2024, Bora received 6 reports related to packaging defects or appearance. None affected safety, and no recalls were required.
Customer Service and Consumer Care
Bora Health Inc. provides a customer hotline and email contact on its website. All inquiries are handled by assigned personnel within 1 business day to ensure that consumers’ concerns are resolved promptly. In 2024, Bora received at least 28 proactive inquiries, all of which were addressed in a timely manner.